104 related articles for article (PubMed ID: 12620998)
1. L-1-11C-tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate.
de Boer JR; Pruim J; van der Laan BF; Que TH; Willemsen AT; Albers FW; Vaalburg W
J Nucl Med; 2003 Mar; 44(3):341-6. PubMed ID: 12620998
[TBL] [Abstract][Full Text] [Related]
2. Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma.
de Boer JR; Pruim J; Albers FW; Burlage F; Vaalburg W; van der Laan BF
J Nucl Med; 2004 Dec; 45(12):2052-7. PubMed ID: 15585481
[TBL] [Abstract][Full Text] [Related]
3. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas.
de Boer JR; van der Laan BF; Pruim J; Que TH; Burlage F; Krikke A; Willemsen AT; Tiebosch AT; Albers FW; Vaalburg W
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1182-7. PubMed ID: 12192563
[TBL] [Abstract][Full Text] [Related]
4. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.
Kole AC; Pruim J; Nieweg OE; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 Feb; 38(2):191-5. PubMed ID: 9025733
[TBL] [Abstract][Full Text] [Related]
5. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
6. Visualisation and assessment of the protein synthesis rate of lung cancer using carbon-11 tyrosine and positron emission tomography.
Pieterman R; Willemsen A; Appel M; Pruim J; Koëter G; Vaalburg W; Groen H
Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):243-7. PubMed ID: 11926387
[TBL] [Abstract][Full Text] [Related]
7. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Paquet N; Albert A; Foidart J; Hustinx R
J Nucl Med; 2004 May; 45(5):784-8. PubMed ID: 15136627
[TBL] [Abstract][Full Text] [Related]
8. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
9. Therapy evaluation of laryngeal carcinomas by tyrosine-pet.
De Boer JR; Pruim J; Burlage F; Krikke A; Tiebosch AT; Albers FW; Vaalburg W; Van Der Laan BF
Head Neck; 2003 Aug; 25(8):634-44. PubMed ID: 12884346
[TBL] [Abstract][Full Text] [Related]
10. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET.
Willemsen AT; van Waarde A; Paans AM; Pruim J; Luurtsema G; Go KG; Vaalburg W
J Nucl Med; 1995 Mar; 36(3):411-9. PubMed ID: 7884503
[TBL] [Abstract][Full Text] [Related]
11. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
[TBL] [Abstract][Full Text] [Related]
12. Carbon-11-methionine uptake in squamous cell head and neck cancer.
Lindholm P; Leskinen S; Lapela M
J Nucl Med; 1998 Aug; 39(8):1393-7. PubMed ID: 9708515
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
14. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
[TBL] [Abstract][Full Text] [Related]
15. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter.
Yeung HW; Sanches A; Squire OD; Macapinlac HA; Larson SM; Erdi YE
Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):61-6. PubMed ID: 11807608
[TBL] [Abstract][Full Text] [Related]
16. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer.
Hallett WA; Marsden PK; Cronin BF; O'Doherty MJ
Eur J Nucl Med; 2001 Jul; 28(7):919-22. PubMed ID: 11504091
[TBL] [Abstract][Full Text] [Related]
17. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional clinical PET in lung cancer: validation and practical strategies.
Calvo R; Martí-Climent JM; Richter JA; Peñuelas I; Crespo-Jara A; Villar LM; García-Velloso MJ
J Nucl Med; 2000 Mar; 41(3):439-48. PubMed ID: 10716316
[TBL] [Abstract][Full Text] [Related]
19. FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy.
Kole AC; Plaat BE; Hoekstra HJ; Vaalburg W; Molenaar WM
J Nucl Med; 1999 Mar; 40(3):381-6. PubMed ID: 10086699
[TBL] [Abstract][Full Text] [Related]
20. Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas.
Plaat B; Kole A; Mastik M; Hoekstra H; Molenaar W; Vaalburg W
Eur J Nucl Med; 1999 Apr; 26(4):328-32. PubMed ID: 10199937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
